



2021 International Congress on Myeloproliferative Neoplasms

October 28-29, 2021 ■ Brooklyn, New York

Letter from the Chairmen

Dear Friends and Colleagues,

It gives us great pleasure to announce the **2021 International Congress on Myeloproliferative Neoplasms**, (2021 MPN Congress), scheduled for October 28-29, 2021 at the New York Marriott at the Brooklyn Bridge in Brooklyn, New York. The 2021 MPN Congress is designed as a hybrid event this year, so all content will be available on the virtual platform for those unable to travel.

This year marks the 20th anniversary of the MPN Congress, an event that has become very popular over the past two decades- providing timely, relevant and meaningful information concerning the diagnosis and treatment of myeloproliferative neoplasms to attendees from around the world. The highly anticipated MPN Congress has always emphasized faculty interaction, audience participation and personal, collegial discussion among attendees, all of which have contributed significantly to the success of this meeting over the years.

The program for the 2021 MPN Congress will offer new information on the prognostic significance of leukocytosis in polycythemia vera, an approach to the differential diagnosis of hereditary erythrocytosis, an update on the clinical status of currently used MPN drugs, as well as new agents of potential value in the MPNs. The role of inflammation in conjunction with the biology and treatment of fatigue in MPN patients, and ruxolitinib-associated weight gain will be discussed.

Other presentations will include the new ELN recommendations for CML treatment, the hypereosinophilias, the status of diagnosis and therapy of mastocytosis, and an update on clinical predictors helpful in MPN transplantation decisions. The differential diagnosis of thrombocytosis and the significance of clonal hematopoiesis, the prognostic role of NGS in MPNs, as well as a review of Covid-19 and its impact on the management of MPNs will round out the program.

At least 300 hematologists/oncologists and other healthcare professionals are expected to attend the in-person, 1.5-day event, with additional attendees joining the meeting virtually. The program features a world class faculty and offers CME credit (including ABIM MOC credit) for physicians and CE for nurses and nurse practitioners.

We look forward to welcoming you to Brooklyn during one of the most beautiful times of the year to connect with colleagues and participate in this productive and informative event!

Richard T. Silver, MD

Weill Cornell Medicine, New York, New York

Chairman, 2021 International Congress on Myeloproliferative Neoplasms

Jerry L. Spivak, MD

Johns Hopkins University School of Medicine, Baltimore, Maryland

Co-Chairman, 2021 International Congress on Myeloproliferative Neoplasms

Faculty

Program Chairs:

Richard T. Silver, MD
Weill Cornell Medicine
New York, New York, USA

Jerry L. Spivak, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland, USA

Program Faculty:

Ghaith Abu-Zeinah, MD
Weill Cornell Medicine
New York, New York, USA

John Mascarenhas, MD
Tisch Cancer Institute
Mount Sinai School of Medicine
New York, New York, USA

Tiziano Barbui, MD
Research Foundation
Ospedale Papa Giovanni XXIII
Bergamo, Italy

Mary Frances McMullin, MD
Queens University Belfast
Belfast City Hospital
Belfast, United Kingdom

Robert P. Gale MD, PhD
Imperial College London
London, United Kingdom

Ruben A. Mesa, MD
Mays Cancer Center at
UT Health San Antonio MD Anderson
San Antonio, Texas, USA

Yelena Ginzburg, MD
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, New York, USA

Laura C. Michaelis, MD
Medical College of Wisconsin
Milwaukee, Wisconsin, USA

Sergio A. Giral, MD
Weill Cornell Medicine
Memorial Sloan-Kettering
Cancer Center
New York, New York, USA

Alison Moliterno, MD
Johns Hopkins University
School of Medicine
Baltimore, Maryland, USA

Heinz Gisslinger, MD
Medical University of Vienna
Vienna, Austria

Naveen Pemmaraju, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas, USA

Hans Hasselbalch, MD, PhD
Roskilde Hospital
University of Copenhagen
Copenhagen, Denmark

Joseph M. Scandura, MD, PhD
Weill Cornell Medicine
New York-Presbyterian Hospital
New York, New York, USA

Rüdiger Hehlmann, MD, PhD
ELN-Foundation
Weinheim, Germany

Andrew I. Schafer, MD
Weill Cornell Medicine
New York, New York, USA

Ronald Hoffman, MD
Tisch Cancer Institute
Mount Sinai School of Medicine
New York, New York, USA

Peter Valent, Prof, MD
Medical University of Vienna
Vienna, Austria

Craig Kessler, MD
Georgetown University
School of Medicine
Washington, DC, USA

Alessandro M. Vannucchi, MD
Careggi University Hospital/
University of Florence
Florence, Italy

Jean-Jacques Kiladjian, MD, PhD
Paris Diderot University
Saint Louis Hospital
Paris, France

Srdan Verstovsek, MD, PhD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas, USA

Amy D. Klion, MD
NIAID/DIR
Bethesda, Maryland, USA

Abstract Committee:

Jerry L. Spivak, MD (Chair)
Robert P. Gale, MD, PhD
Naveen Pemmaraju, MD

AGENDA

Thursday, October 28, 2021

7:00-7:45 am BREAKFAST/Industry Expert Session

SESSION I

Session Co-Chairs: Jerry Spivak, MD, & Richard Silver, MD

8:00-8:10 am Welcome and Introduction

8:10-8:40 am Hereditary erythrocytosis

8:40-9:10 am Thrombocytosis: benign and malignant

9:10-9:40 am Leukocytosis in PV: prognostic and therapeutic implications

9:40-10:10 am MPN stem cell fitness is linked to clinical outcomes

10:10-10:35 am BREAK

SESSION II

Session Co-Chairs: Joseph Scandura, MD PhD & Alison Moliterno, MD

10:35-11:05 am JAK2V617F and clonal hematopoiesis

11:05-11:35 am NGS in MPN diagnosis and treatment: update

11:35-12:05 pm Candidate drugs to prevent MPN progression

12:15-1:15 pm LUNCH/Industry Expert Session

SESSION III

Session Co-Chairs: Hans Hasselbalch, MD, PhD & Srdan Verstovsek, MD, PhD

1:20-1:50 pm Update on the clinical status of commonly used drugs in PMF

1:50-2:20 pm New agents of potential value in the MPN

2:20-2:50 pm Update of phase 3 trials of rIFN α in polycythemia vera

2:50-3:20 pm BREAK

SESSION IV

Session Co-Chairs: Andrew Schafer, MD & Ruben Mesa, MD

3:20-3:50 pm Exploiting iron metabolism to treat PV

3:50-4:20 pm What's new in the hypereosinophilic syndrome?

4:20-4:50 pm Diagnostic evaluation and therapy in mastocytosis: status 2021

4:50-5:15 pm Abstract presentation (Award Winner)

5:15-7:00 pm WELCOME RECEPTION & POSTER PRESENTATIONS

Friday, October 29, 2021

7:00-7:45 am BREAKFAST/Industry Expert Session

SESSION V

Session Co-Chairs: Rüdiger Hehlmann, MD & Naveen Pemmaraju, MD

8:00-8:30 am Covid-19 and the MPN

8:30-9:00 am The role of inflammation in the MPN

9:00-9:30 am Treatment of early PMF

9:30-10:00 am Treatment of low risk PV

10:00-10:30 am Interferon improves myelofibrosis and overall survival

10:30-11:00 am BREAK

SESSION VI

Session Co-Chairs: Jean-Jacques Kiladjian, MD, PhD & Ronald Hoffman, MD

11:00-11:45 am New ELN recommendations for CML

11:45-12:15 pm Which published schema are helpful in MPN transplant decisions?

12:15-12:45 pm Anticoagulant management in the MPN

12:45-1:15 pm The limitations of clinical trials

1:15-1:25 pm Closing Remarks

1:25 pm ADJOURN

Richard T. Silver, MD

Mary Frances McMullin, MD

Jerry L. Spivak, MD

John Mascarenhas, MD

Joseph M. Scandura, MD, PhD

Alison Moliterno, MD

Alessandro M. Vannucchi, MD

Ronald Hoffman, MD

Srdan Verstovsek, MD, PhD

Naveen Pemmaraju, MD

Heinz Gisslinger, MD

Yelena Ginzburg, MD

Amy D. Klion, MD

Peter Valent, MD

TBD

Laura Michaelis, MD

Hans Hasselbalch, MD, PhD

Ruben Mesa, MD

Tiziano Barbui, MD

Ghaith Abu-Zeinah, MD / Richard T. Silver, MD

Rüdiger Hehlmann, MD

Sergio Giral, MD

Craig Kessler, MD

Robert P. Gale, MD, PhD

Richard T. Silver, MD



GENERAL INFORMATION

Registration

Register online at www.MPNcongress.com. Inquiries may be directed via email to info@MeltonMedEd.com or by phone to 512-619-5534. Registration confirmations and all meeting updates will be sent via email.

Registration Fees	Early (before 9/1)	Standard (9/2- 10/23)	Late & Onsite (begins 10/24)
Physician	\$199	\$299	\$399
PA, Nurse, Fellow, Resident, Other	\$99	\$149	\$199
Exhibitor/Industry	\$299	\$449	\$549

Payment: Registration fees must be remitted by credit card or check. Checks should be payable to Melton Medical Education, LLC. Payment must be in U.S. Currency, and checks must be drawn on a U.S. bank. Attendee is not registered until full payment is received.

Fee Inclusions: Registration fees include conference materials, admittance to all scientific sessions, processing of certificates of attendance or continuing medical education, and all event meals and functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at info@MeltonMedEd.com no later than Oct 23, 2021. The amount of registration fees remitted, minus a \$50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. **No refunds will be made if notice is received after Oct 23, 2021.**

Location & Accommodations

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, NY, 11201
Tel: (718) 246-7000
Book online: <https://book.passkey.com/go/mpn2021>



The 2021 International Congress on Myeloproliferative Neoplasms will be held at the New York Marriott at the Brooklyn Bridge. For the convenience of attendees, a room block with a limited number of rooms has been reserved at the discounted group rate of \$239.00 (plus taxes/fees). This limited number of discounted rooms will be available until October 4, 2021. Reservations received after October 4, 2021 or after the room block has been filled (whichever comes first) are subject to availability and prevailing hotel rates. To obtain the discounted rate, you may book your hotel room online at <https://book.passkey.com/go/mpn2021> or by calling the hotel directly at 718-246-7000. Mention that you are with the 2021 International MPN Congress to receive the discounted rate. (Cost for traditional double/double room is \$254).

Continuing Medical Education/Continuing Education Accreditation

For Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Medical and Nursing Education, Inc. and Melton Medical Education, LLC. The Institute for Medical and Nursing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

IMNE designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits.[™] Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For Nurses: The Institute for Medical and Nursing Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational program provides 11.25 contact hours of continuing nursing education credit.

For any questions regarding the CME or CE credit being offered for this meeting, please contact Steve Weinman, RN at steveweinman@imne.com

Target Audience:

This educational activity is intended for hematologists, medical oncologists, translational scientists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myeloproliferative neoplasms and related disorders.

Educational Objectives:

Upon completion, participants should be able to:

- Understand the molecular pathogenesis of myeloproliferative neoplasms (MPNs) and related disorders.
- Discuss the role and utilization of current approved therapies in MPNs, including the recent advances in therapeutics.
- Describe the potential role of agents in development for MPNs.
- Assess how to manage symptoms and therapy-associated adverse events for patients with MPNs.
- Outline the current treatment strategies (including first-line therapy, milestones, changing treatment, discontinuation and pregnancy) for patients with chronic myeloid leukemia (CML).

Meeting Organizer
Melton
Medical Education, LLC

PO Box 341414, Austin, TX 78734

Phone: (512) 619-5534

Email: info@MeltonMedEd.com

www.MPNcongress.com




2021 International Congress on Myeloproliferative Neoplasms

October 28-29, 2021 ■ Brooklyn, New York



Melton Medical Education, LLC
PO Box 341414
Austin, TX 78734



Support Opportunities

The 2021 International Congress on Myeloproliferative Neoplasms offers a forum for industry supporters to participate in the exchange of information and ideas surrounding the most recent updates and debates in the diagnosis and management of MPNs. The planning committee, faculty and attendees alike appreciate the support of our industry partners.

There are many opportunities for industry to support the conference via tradeshow exhibition, industry expert session participation, exclusive supporter options and others. Each opportunity promises to provide a significant presence for companies during the conference.

For more information, contact Melton Medical Education by email at info@meltonmeded.com or phone at (512) 619-5534.



Call for Abstracts

Submission Deadline: September 19, 2021

The 2021 International Congress on Myeloproliferative Neoplasms' Organizing Committee encourages participants to submit an abstract for publication in the program book and for poster presentation during the event. In addition, the best abstract (as determined by the Abstract Committee) will be awarded a travel grant, as well as the opportunity to give an oral presentation during the congress.

The committee seeks original papers that address basic or clinical issues specifically related to the diagnosis or management of patients with MPNs and related disorders. The body of the abstract is limited to 500 words or less and must represent original work, although previously published work may be used to fulfil this requirement. Presentations are not disqualified from submission to the annual ASH meeting.

Participants interested in presenting data can submit abstracts to abstracts@mpncongress.com on or before **September 19, 2021**. Abstracts are subject to acceptance by the Abstract Committee. All those accepted for abstract/poster presentation will receive a complimentary registration to attend the conference. Note that reimbursement for travel and hotel expenses is not provided.

Important Dates

April 28	Abstract Submission Opens
July 28	Exhibit/Support Opportunities Application Deadline
Sept 1	Early Registration Deadline
Sept 19	Abstract Submission Closes
Oct 4	Hotel Reservation Group Rate Deadline
Oct 23	Standard Registration Deadline
Oct 28-29	2021 International MPN Congress

www.MPNcongress.com

